Intro

This chapter explores the promising results of Eli Lilly's drug ZepBow in a phase three trial, which showed a significantly higher average weight loss compared to Nordisk's Wigobi. The findings suggest ZepBow may redefine expectations in the weight loss treatment market.

Transcript

Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app